For Patients & Caregivers

Do you have patients in your practice who are eligible for ENSPRYNG?

These example patients may help you identify appropriate patients for ENSPRYNG in your practice

Meet Garcelle* | 35 years | Newly diagnosed3

Garcelle works full-time and cares for her 2 children.

Select medical history
  • Initially misdiagnosed with MS and began MS treatment 8 months ago; symptoms did not fully resolve1
  • Had an attack 2 months ago and was given high-dose IV steroids3
  • Tested positive for AQP4 antibodies, confirming the diagnosis of AQP4-IgG+ NMOSD3
Clinical presentation1,3
  • Experiences partial vision loss, has numbness and weakness in her legs
  • EDSS score is 4.0
Patient goal
  • Wants to get on a treatment as soon as possible to control her symptoms but doesn’t want it to get in the way of her busy lifestyle
Choose ENSPRYNG for your appropriate adult patients with AQP4-IgG(+) NMOSD3

Meet Lucy* | 42 years | On IST monotherapy3

Lucy works full-time and lives in a rural area.

Select medical history3
  • Diagnosed with AQP4-IgG+ NMOSD 2 years ago
  • Had an acute attack within the past year, recovered almost fully, but not completely back to baseline
  • Currently taking azathioprine
Clinical presentation
  • In the past month, she’s had moderate blurred vision in her left eye, tingling sensations in her lower limbs, and has lost her balance a few times. She reported no new weakness or pain1
  • EDSS score 4.53
Patient goal
  • Concerned her current treatment alone isn’t enough to prevent a future NMOSD relapse
Choose ENSPRYNG for your appropriate adult patients with AQP4-IgG(+) NMOSD3

Meet Sarah* | 46 years | On a biologic therapy3,47

Sarah works part-time and loves to travel.

Select medical history
  • Diagnosed with AQP4-IgG+ NMOSD 10 years ago
  • Previous relapse of optic neuritis and transverse myelitis in the last year3
  • Currently taking an anti-CD20 monoclonal antibody for maintenance therapy47
  • Has diabetes46
Clinical presentation
  • She is still fully ambulatory, but she sometimes experiences bladder and bowel dysfunction1
  • Experiences recurrent urinary tract infections1
  • EDSS score 3.53
Patient goal
  • Worried about continued infections impacting her life over the long term and wants to find a better solution4,5
Choose ENSPRYNG for your appropriate adult patients with AQP4-IgG(+) NMOSD3

*Not a real patient.
EDSS=Expanded Disability Status Scale; IST=immunosuppressive therapy; IV=intravenous; MS=multiple sclerosis.

Icon showing a check mark
ENSPRYNG has a well-studied safety profile4

Patients had a median of 5 years exposure to ENSPRYNG across clinical trials

View data
ENSPRYNG clinical trial results

Explore efficacy results for ENSPRYNG across two distinct phase 3 trials

View data

Important Safety Information & Indication

Indication

ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Contraindications

ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.

Warnings and Precautions

Infections
An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including ENSPRYNG. The most common infections reported in a randomized clinical trial of patients treated with ENSPRYNG who were not on other chronic immunosuppressant therapies, and that occurred more often than in patients receiving placebo, were nasopharyngitis (12%) and cellulitis (10%). The most common infections in patients who were on an additional concurrent immunosuppressant, and that occurred more often than in patients receiving placebo, were nasopharyngitis (31%), upper respiratory infection (19%), and pharyngitis (12%). Delay ENSPRYNG administration in patients with an active infection, including localized infections, until the infection is resolved.

Hepatitis B Virus (HBV) Reactivation
Risk of HBV reactivation has been observed with other immunosuppressant therapies. Patients with chronic HBV infection were excluded from clinical trials. Perform HBV screening in all patients before initiation of treatment with ENSPRYNG. Do not administer ENSPRYNG to patients with active hepatitis. For patients who are chronic carriers of HBV [HBsAg+] or are negative for HBsAg and positive for HB core antibody [HBcAb+], consult liver disease experts before starting and during treatment with ENSPRYNG.

Tuberculosis
Tuberculosis has occurred in patients treated with other IL-6 receptor antagonists. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ENSPRYNG. Consider anti-tuberculosis therapy prior to initiation of ENSPRYNG in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment. Patients should be monitored for the development of signs and symptoms of tuberculosis with ENSPRYNG, even if initial tuberculosis testing is negative.

Vaccinations
Live or live-attenuated vaccines should not be given concurrently with ENSPRYNG because clinical safety has not been established. Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ENSPRYNG for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ENSPRYNG for non-live vaccines.

Elevated Liver Enzymes
Mild and moderate elevations of liver enzymes have been observed in patients treated with ENSPRYNG at a higher incidence than in patients receiving placebo. ALT and AST levels should be monitored every 4 weeks for the first 3 months of treatment, followed by every 3 months for one year, and thereafter, as clinically indicated.

Decreased Neutrophil Counts
Decreases in neutrophil counts were observed in patients treated with ENSPRYNG at a higher incidence than placebo. Neutrophil counts should be monitored 4 to 8 weeks after initiation of therapy, and thereafter at regular clinically determined intervals.

Hypersensitivity Reactions
Hypersensitivity reactions, including rash, urticaria, and fatal anaphylaxis, have occurred with other IL-6 receptor antagonists.

Use in Specific Populations

Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ENSPRYNG during pregnancy. Healthcare providers are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-833-277-9338.

There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In an animal reproduction study, no adverse effects on maternal animals or fetal development were observed in pregnant monkeys and their offspring, with administration of ENSPRYNG at doses up to 50 mg/kg/week. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2 – 4% and 15 – 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Lactation
No information is available on the presence of ENSPRYNG in human milk, the effects of ENSPRYNG on the breastfed infant, or the effects of ENSPRYNG on milk production. ENSPRYNG was excreted in the milk of lactating monkeys administered ENSPRYNG throughout pregnancy. Human IgG is excreted in human milk and the potential for absorption in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

Geriatric Use
Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, population pharmacokinetic analyses in patients with NMOSD did not show that age affected the pharmacokinetics of ENSPRYNG. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.

Most Common Adverse Reactions
The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see the full Prescribing Information and Medication Guide.

    • Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114. doi:10.1212/wnl.53.5.1107

      Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114. doi:10.1212/wnl.53.5.1107

    • George M, Gantioque R. Neuromyelitis optica spectrum disorder: an early diagnosis to prevent blindness and paraplegia. J Nurse Pract. 2023;19(7):104654. doi:10.1016/j.nurpra.2023.104654

      George M, Gantioque R. Neuromyelitis optica spectrum disorder: an early diagnosis to prevent blindness and paraplegia. J Nurse Pract. 2023;19(7):104654. doi:10.1016/j.nurpra.2023.104654

    • ENSPRYNG [prescribing information]. South San Francisco, CA: Genetech, Inc. 2022.

      ENSPRYNG [prescribing information]. South San Francisco, CA: Genetech, Inc. 2022.

    • Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA.

      Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA.

    • Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. doi:10.1016/j.msard.2022.104025

      Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. doi:10.1016/j.msard.2022.104025

    • FDA approves Genentech’s Enspryng for neuromyelitis optica spectrum disorder. News release. Genentech, Inc. August 14, 2020. Accessed February 10, 2025. https://www.gene.com/media/press-releases/14873/2020-08-14/fdaapproves-genentechs-enspryng-for-neu

      FDA approves Genentech’s Enspryng for neuromyelitis optica spectrum disorder. News release. Genentech, Inc. August 14, 2020. Accessed February 10, 2025. https://www.gene.com/media/press-releases/14873/2020-08-14/fdaapproves-genentechs-enspryng-for-neu

    • Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727. doi:10.1038/s41598-020-73882-8

      Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727. doi:10.1038/s41598-020-73882-8

    • Anderson M, Levy M. Advances in the long-term treatment of neuromyelitis optica spectrum disorder. J Cent Nerv Syst Dis. 2024;16:11795735241231094. doi:10.1177/11795735241231094

      Anderson M, Levy M. Advances in the long-term treatment of neuromyelitis optica spectrum disorder. J Cent Nerv Syst Dis. 2024;16:11795735241231094. doi:10.1177/11795735241231094

    • Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today. 2021;26(7):1591-1601. doi:10.1016/j.drudis.2021.03.018

      Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today. 2021;26(7):1591-1601. doi:10.1016/j.drudis.2021.03.018

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management [published correction appears in J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2.]. J Neurol. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z

      Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management [published correction appears in J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2.]. J Neurol. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z

    • Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-164. doi:10.1111/cei.12271

      Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-164. doi:10.1111/cei.12271

    • Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412. doi:10.1016/S1474-4422(20)30078-8

      Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412. doi:10.1016/S1474-4422(20)30078-8

    • Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114-2124. doi:10.1056/NEJMoa1901747

      Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114-2124. doi:10.1056/NEJMoa1901747

    • Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176. doi:10.7861/clinmedicine.19-2-169

      Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-176. doi:10.7861/clinmedicine.19-2-169

    • Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-3706. doi:10.1073/pnas.1017385108

      Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-3706. doi:10.1073/pnas.1017385108

    • Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137-145. doi:10.1136/jnnp-2016-313300

      Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137-145. doi:10.1136/jnnp-2016-313300

    • Briggs FB, Shaia J. Prevalence of neuromyelitis optica spectrum disorder in the United States. Mult Scler. Published online January 27, 2024. doi:10.1177/13524585231224683

      Briggs FB, Shaia J. Prevalence of neuromyelitis optica spectrum disorder in the United States. Mult Scler. Published online January 27, 2024. doi:10.1177/13524585231224683

    • Glisson CC. Neuromyelitis optica spectrum disorder (NMOSD): clinical features and diagnosis. UpToDate website. Updated January 7, 2025. Accessed February 10, 2025. https://www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorder-nmosd-clinical-features-and-diagnosis.

      Glisson CC. Neuromyelitis optica spectrum disorder (NMOSD): clinical features and diagnosis. UpToDate website. Updated January 7, 2025. Accessed February 10, 2025. https://www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorder-nmosd-clinical-features-and-diagnosis.

    • Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. doi:10.1016/S1474-4422(07)70216-8

      Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. doi:10.1016/S1474-4422(07)70216-8

    • Knapp RK, Hardtstock F, Wilke T, et al. Evaluating the economic burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data. Neurol Ther. 2022;11(1):247-263. doi:10.1007/s40120-021-00311-x

      Knapp RK, Hardtstock F, Wilke T, et al. Evaluating the economic burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data. Neurol Ther. 2022;11(1):247-263. doi:10.1007/s40120-021-00311-x

    • Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice [published correction appears in Mult Scler Relat Disord. 2021 Jul;52:103026. doi: 10.1016/j.msard.2021.103026.]. Mult Scler Relat Disord. 2020;45:102428. doi:10.1016/j.msard.2020.102428

      Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice [published correction appears in Mult Scler Relat Disord. 2021 Jul;52:103026. doi: 10.1016/j.msard.2021.103026.]. Mult Scler Relat Disord. 2020;45:102428. doi:10.1016/j.msard.2020.102428

    • Heo YA. Correction to: Satralizumab: First Approval. Drugs. 2020;80(14):1483. doi:10.1007/s40265-020-01391-z

      Heo YA. Correction to: Satralizumab: First Approval. Drugs. 2020;80(14):1483. doi:10.1007/s40265-020-01391-z

    • Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. doi:10.1212/NXI.0000000000000311

      Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. doi:10.1212/NXI.0000000000000311

    • Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-1596. doi:10.1038/nm.3407

      Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-1596. doi:10.1038/nm.3407

    • Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729

      Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729

    • Shah K, Maghsoudlou P. Enzyme-linked immunosorbent assay (ELISA): the basics. Br J Hosp Med (Lond). 2016;77(7):C98-C101. doi:10.12968/hmed.2016.77.7.C98

      Shah K, Maghsoudlou P. Enzyme-linked immunosorbent assay (ELISA): the basics. Br J Hosp Med (Lond). 2016;77(7):C98-C101. doi:10.12968/hmed.2016.77.7.C98

    • Jeyalatha MV, Therese KL, Anand AR. An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders. J Clin Neurol. 2022;18(2):152-162. doi:10.3988/jcn.2022.18.2.152

      Jeyalatha MV, Therese KL, Anand AR. An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders. J Clin Neurol. 2022;18(2):152-162. doi:10.3988/jcn.2022.18.2.152

    • Smith AD, Moog TM, Burgess KW, McCreary M, Okuda DT. Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2023;70:104498. doi:10.1016/j.msard.2023.104498

      Smith AD, Moog TM, Burgess KW, McCreary M, Okuda DT. Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2023;70:104498. doi:10.1016/j.msard.2023.104498

    • Neuromyelitis optica spectrum disorder. National Organization for Rare Disorders website. Updated July 27, 2022. Accessed February 20, 2025. https://rarediseases.org/rare-diseases/neuromyelitis-optica/.

      Neuromyelitis optica spectrum disorder. National Organization for Rare Disorders website. Updated July 27, 2022. Accessed February 20, 2025. https://rarediseases.org/rare-diseases/neuromyelitis-optica/.

    • Long Y, Liang J, Wu L, et al. Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. Front Neurol. 2017;8:62. doi:10.3389/fneur.2017.00062

      Long Y, Liang J, Wu L, et al. Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. Front Neurol. 2017;8:62. doi:10.3389/fneur.2017.00062

    • Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-1173. doi:10.1212/WNL.0000000000001367

      Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-1173. doi:10.1212/WNL.0000000000001367

    • Cheng C, Jiang Y, Lu X, et al. The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol. 2016;16(1):203. doi:10.1186/s12883-016-0721-1

      Cheng C, Jiang Y, Lu X, et al. The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol. 2016;16(1):203. doi:10.1186/s12883-016-0721-1

    • Paul F, Marignier R, Palace J, et al. International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi:10.1212/NXI.0000000000200124

      Paul F, Marignier R, Palace J, et al. International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi:10.1212/NXI.0000000000200124

    • Delgado-Garcia G, Lapidus S, Talero R, Levy M. The patient journey with NMOSD: From initial diagnosis to chronic condition. Front Neurol. 2022;13:966428. doi:10.3389/fneur.2022.966428

      Delgado-Garcia G, Lapidus S, Talero R, Levy M. The patient journey with NMOSD: From initial diagnosis to chronic condition. Front Neurol. 2022;13:966428. doi:10.3389/fneur.2022.966428

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • SOLIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc. 2024.

      SOLIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc. 2024.

    • ULTOMIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc. 2024.

      ULTOMIRIS [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc. 2024.

    • UPLIZNA [prescribing information]. Deerfield, IL: Horizon Therapeutics USA, Inc. 2021.

      UPLIZNA [prescribing information]. Deerfield, IL: Horizon Therapeutics USA, Inc. 2021.

    • FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD). Media release. Roche. August 16, 2020. Accessed February 10, 2025. https://www.roche.com/media/releases/med-cor-2020-08-17#:~:text=Roche%20(SIX%3A%20RO%2C%20ROG,optica%20spectrum%20disorder%20(NMOSD).

      FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD). Media release. Roche. August 16, 2020. Accessed February 10, 2025. https://www.roche.com/media/releases/med-cor-2020-08-17#:~:text=Roche%20(SIX%3A%20RO%2C%20ROG,optica%20spectrum%20disorder%20(NMOSD).

    • Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480-489. doi:10.1111/cei.12733

      Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480-489. doi:10.1111/cei.12733

    • Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60-67. doi:10.1016/S1474-4422(20)30392-6

      Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60-67. doi:10.1016/S1474-4422(20)30392-6

    • Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02073279. Updated March 1, 2023. Accessed February 10, 2025. https:// clinicaltrials.gov/study/NCT02073279

      Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02073279. Updated March 1, 2023. Accessed February 10, 2025. https:// clinicaltrials.gov/study/NCT02073279

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Efficacy and safety study of satralizumab (SA237) as add-on therapy to treat participants with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02028884. Updated April 18, 2023. Accessed February 10, 2025. https://clinicaltrials.gov/ study/NCT02028884

      Efficacy and safety study of satralizumab (SA237) as add-on therapy to treat participants with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02028884. Updated April 18, 2023. Accessed February 10, 2025. https://clinicaltrials.gov/ study/NCT02028884

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    • Kleiter I, Traboulsee A, Palace J, et al. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. doi:10.1212/NXI.0000000000200071

      Kleiter I, Traboulsee A, Palace J, et al. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. doi:10.1212/NXI.0000000000200071

    • Data on file. Genentech, Inc. South San Francisco, CA.

      Data on file. Genentech, Inc. South San Francisco, CA.

    TOP